All products
GLP3-RT

Research Products

GLP3-RT

Retatrutide · 30mg

In Stock · SKU RT30

Retatrutide is an experimental compound being studied for its effects on appetite, blood sugar and the way the body uses energy. Researchers are interested in it because it acts on three hormone receptors rather than just one. It is not approved for human use.

Available options

GLP3-RT

30mg · 3ml Vial

In Stock

$145.00

View cart & checkout →

For laboratory research only. Not for human consumption or medical use. Published research does not establish the safety or identity of a specific supplied vial.

Research explained

What is Retatrutide?

Retatrutide is an experimental compound being studied for its effects on appetite, blood sugar and the way the body uses energy. Researchers are interested in it because it acts on three hormone receptors rather than just one. It is not approved for human use.

How does it work?

The compound activates three receptors: GLP-1, GIP and glucagon. Together, these signaling pathways play roles in appetite, blood glucose regulation and energy metabolism. Activating all three is being investigated in controlled research.

Product specifications

Compound
Retatrutide
Research code
LY3437943
SKU
RT30
Labeled strength
30mg
Packaging
3ml Vial

Product-specific details are from the Vendure catalog. Purity and testing claims should only be used when backed by batch-specific evidence.

Mechanism and research areas

What are scientists studying?

Appetite and fullness

Studies investigate how hormonal signaling changes hunger and fullness.

Blood sugar regulation

Researchers examine how these receptors influence glucose and insulin-related responses.

Energy metabolism

Experiments explore how adding glucagon-receptor activity changes energy regulation.

Published research

What have studies found?

A randomized phase 2 study enrolled 338 adults with obesity or overweight and a weight-related condition. After 48 weeks, the 12 mg investigational-treatment group had an estimated average 24.2% reduction in body weight, compared with 2.1% in the placebo group.

The trial tested investigational pharmaceutical material under medical supervision. Gastrointestinal side effects were common and increases in heart rate were observed. These results do not establish the quality, safety or effect of a retail research vial, and they are not instructions for use.

Randomized, double-blind, placebo-controlled phase 2 clinical trial · 2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff AM et al. · New England Journal of Medicine · DOI: 10.1056/NEJMoa2301972

Reported dose-dependent changes in average body weight over 48 weeks in a controlled investigational trial.

Limitations: Safety follow-up was limited; pharmaceutical clinical-trial material is not equivalent to a commercial research sample.

Read original publication

Quality documentation

Batch testing and COAs

Certificates of analysis must be matched to a specific batch. No test result, purity figure or third-party verification is implied unless the corresponding document is provided.

Ask about batch documentation →

Additional product information